

Failure to Launch: The Patent Thicket Delay of U.S. Biosimilars

October 9, 2019

ATTORNEYS

Ankerman, Chantelle

Mathias, Ted

Ropka, PhD, Stacie

PRACTICE AREAS

Biotechnology

Intellectual Property

Ted Mathias, Stacie Ropka, PhD, and Chantelle Ankerman
Law360

Axinn partners Ted Mathias, Stacie Ropka, and associate Chantelle Ankerman authored the *Law360* article, "Failure to Launch: The Patent Thicket Delay of U.S. Biosimilars."

[Click here](#) to access the article. A subscription is required.